| 2.76 0.07 (2.6%) | 04-08 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 3.57 | 1-year : | 4.02 |
| Resists | First : | 3.06 | Second : | 3.45 |
| Pivot price | 2.85  |
|||
| Supports | First : | 2.43 | Second : | 2.02 |
| MAs | MA(5) : | 2.65 |
MA(20) : | 2.93 |
| MA(100) : | 3.18 |
MA(250) : | 5.02 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 31.9 |
D(3) : | 24.1 |
| RSI | RSI(14): 43.9 |
|||
| 52-week | High : | 20.7 | Low : | 2.43 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CLRB ] has closed above bottom band by 41.0%. Bollinger Bands are 12.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.82 - 2.83 | 2.83 - 2.84 |
| Low: | 2.73 - 2.74 | 2.74 - 2.75 |
| Close: | 2.74 - 2.76 | 2.76 - 2.77 |
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; IntoCell Inc; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.
Fri, 03 Apr 2026
Earnings call transcript: Cellectar Biosciences Q4 2025 reveals strategic cost control - Investing.com
Sun, 22 Mar 2026
If You Invested $1,000 in Cellectar Biosciences Inc (CLRB) - Stock Titan
Mon, 09 Mar 2026
Cellectar Biosciences Charts Risky Path to Approvals - TipRanks
Thu, 05 Mar 2026
Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q4 2025 Earnings Call Transcript - Insider Monkey
Wed, 04 Mar 2026
Cellectar Biosciences 2025 10-K — Net loss $8.35 EPS; no revenue reported - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 4 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 3.9 (%) |
| Held by Institutions | 8.6 (%) |
| Shares Short | 46 (K) |
| Shares Short P.Month | 117 (K) |
| EPS | -8.36 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.88 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -71.1 % |
| Return on Equity (ttm) | -170.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -5.38 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -23 (M) |
| Levered Free Cash Flow | -16 (M) |
| PE Ratio | -0.34 |
| PEG Ratio | 0 |
| Price to Book value | 1.46 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.51 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|